logo

Axsome Therapeutics, Inc. (AXSM)



Trade AXSM now with
  Date
  Headline
6/5/2018 7:05:10 AM Axsome Therapeutics Initiates Phase 2 Trial Of AXS-05 In Major Depressive Disorder
5/8/2018 7:16:02 AM Axsome Therapeutics Q1 Net Loss $4.8 Mln Or $0.19/Shr Vs Loss Of $8.0 Mln Or $0.41/Shr Last Year
4/23/2018 7:04:33 AM Axsome Therapeutics Says First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation
4/19/2018 7:08:00 AM Axsome Therapeutics Names Nick Pizzie CFO, Effective May 16
3/12/2018 7:12:21 AM Axsome Therapeutics Presents Scientific Rationale For Development Of AXS-05
3/7/2018 7:05:54 AM Axsome Therapeutics Q4 Net Loss $7.4 Mln Or $0.31/Shr Vs Loss Of $7.3 Mln Or $0.38/Shr Last Year
2/26/2018 7:05:24 AM Axsome Therapeutics Announces Primary Endpoint Met In Phase 1 Trial Of Next Generation Product Candidate AXS-09
1/9/2018 7:12:28 AM Axsome: IDMC Recommend COAST-1 Trial Be Continued To Full Enrollment And CREATE-1 Trial Be Stopped For Futility
12/14/2017 7:11:40 AM Axsome Collaborates With Duke University To Evaluate AXS-05 In Phase 2 Clinical Trial In Smokers Attempting To Quit
12/1/2017 7:05:36 AM Axsome Therapeutics Announces $9.5 Mln Direct Offering
11/8/2017 7:08:46 AM Axsome Therapeutics Posts Q3 Net Loss Of $6.4 Mln Or $0.27/share
9/7/2017 7:24:31 AM Axsome Therapeutics Says Interim Analysis Of Phase 3 CREATE-1 Trial Of AXS-02 In CRPS Expected Year-end 2017
8/9/2017 7:19:51 AM Axsome Therapeutics Q2 Net Loss $7.1 Mln Or $0.30/shr Vs. Net Loss $6.8 Mln Or $0.36/shr Last Year
7/17/2017 7:04:47 AM Axsome Therapeutics Begins Phase 2/3 Trial Of AXS-05 For Alzheimer’s Disease Agitation
7/6/2017 7:01:54 AM Axsome Therapeutics Says Appoints John Golubieski As CFO, Effective Aug. 4